Patients responding to one form of hormonal treatment had a greater likelihood of responding to subsequent hormonal manipulations. Additive hormonal therapy may provide effective palliation in males with advanced breast...
[1]https://www.onclive.com/view/antibody-drug-conjugates-expand-her2-breast-cancer-treatment-options [2]DS-8201a in pre-treated HER2 breast cancer that cannot be surgically removed or has spread [DESTINY-Breast02]. ClinicalTrials.gov. Updated August 12, 2022. Accessed November 28, 2022. [3...
乳腺癌是引起脑转移瘤的第二大常见原因,占所有脑转移的15%～20%[1],晚期乳腺癌脑转移(breast cancer brain metastases,BCBM)的比例为10%-15%[2],约0.4%-4.3%的乳腺癌患者初诊时即伴有脑转移[3]。脑转移对乳腺癌患者的生存质量...
[3] Huo X, Shen G, Wang T, et al. Treatment options for patients with human epidermal growth factor 2-positive breast cancer brain metastases: A systematic review and meta-analysis. Front Oncol. 2023;13:1003565. [4] Zimmer AS, Van Swearingen AED, Anders CK. HER2-positive breast cancer ...
[3] Galanti D, Inno A, La Vecchia M, et al. Current treatment options for HER2-positive breast cancer patients with brain metastases. Crit Rev Oncol Hematol. 2021 May;161:103329. [4] Garcia-Alvarez A, Papakonstantinou A, Oliveira M. Br...
Hatem Soliman, MD, discusses the current first-line treatment options for patients with HER2-positive breast cancer.
2. Saini KS, et al. Beyond trastuzumab: new treatment options for HER2-positive breast cancer. Breast. 2011;20(Suppl 3):S20–7. 3. Capelan M, et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol. 2013;24(2):273–82. ...
Targeting breast cancer through this vital oncogenic protein has been a major step towards improved patient outcomes. Today, several anti-HER2 agents are in clinical use including: the monoclonal antibodies trastuzumab and pertuzumab; the small molecule inhibitors lapatinib, neratinib, and tucatinib; and...
[6] Soo Yeon Baek, et al. Adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: 8-year follow-up of the randomized ASTRRA trial. 2022 ASCO. 506. ...
This article reviews the challenges and future options in the treatment of ErbB2- positive metastatic breast cancer. It summarizes a presentation from a symposium that was held at the ECCO 14 congress in 2007. Despite great progress in the management of ErbB2-positive metastatic breast cancer, si...